JMPWA
ACAD icon

JP Morgan Private Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$208K Sell
10,000
-1,058
-10% -$28.7K ﹤0.01% 1620
2023
Q2 		$265K Sell
11,058
-3,445
-24% -$76.6K ﹤0.01% 1287
2023
Q1 		$273K Sell
14,503
-582
-4% -$11.1K ﹤0.01% 1720
2022
Q4 		$240K Buy
+15,085
New +$236K ﹤0.01% 1742
2022
Q1 		– Sell
-15,628
Closed -$365K – 1996
2021
Q4 		$365K Sell
15,628
-1,115
-7% -$22.4K ﹤0.01% 1665
2021
Q3 		$278K Sell
16,743
-61
-0.4% -$1.18K ﹤0.01% 1722
2021
Q2 		$410K Sell
16,804
-1,641
-9% -$37K ﹤0.01% 1554
2021
Q1 		$476K Buy
18,445
+8,655
+88% +$381K ﹤0.01% 1330
2020
Q4 		$523K Buy
9,790
+228
+2% +$11.3K ﹤0.01% 1274
2020
Q3 		$394K Buy
9,562
+1,126
+13% +$48.6K ﹤0.01% 1246
2020
Q2 		$409K Buy
8,436
+39
+0.5% +$1.87K ﹤0.01% 1188
2020
Q1 		$355K Buy
+8,397
New +$346K ﹤0.01% 1067
2017
Q2 		– Sell
-7,703
Closed -$265K – 1232
2017
Q1 		$265K Buy
+7,703
New +$272K ﹤0.01% 1123
2016
Q4 		– Sell
-9,901
Closed -$315K – 1242
2016
Q3 		$315K Buy
9,901
+2,370
+31% +$80.4K ﹤0.01% 971
2016
Q2 		$244K Sell
7,531
-837
-10% -$28K ﹤0.01% 1068
2016
Q1 		$235K Buy
+8,368
New +$182K ﹤0.01% 1028

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

JP Morgan Private Wealth Advisors's ACAD Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 9.6% in Q3 2023, selling an estimated $28.7K and leaving 10,000 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

JP Morgan Private Wealth Advisors first reported a position in ACAD in Q1 2016 and has held it in 16 quarters since. The position peaked at $523K in Q4 2020. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

  • JP Morgan Private Wealth Advisors held 10,000 shares of Acadia Pharmaceuticals worth $208K as of Q3 2023.
  • JP Morgan Private Wealth Advisors sold 1,058 Acadia Pharmaceuticals shares in Q3 2023, an estimated $28.7K.
  • Acadia Pharmaceuticals made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1620 holding.
  • JP Morgan Private Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q1 2016 and has held it in 16 quarters since.
  • JP Morgan Private Wealth Advisors's Acadia Pharmaceuticals position peaked at $523K in Q4 2020.
  • 248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.